Exercise  ||| S:0 E:9 ||| NN
as  ||| S:9 E:12 ||| IN
an  ||| S:12 E:15 ||| DT
end-point  ||| S:15 E:25 ||| JJ
in  ||| S:25 E:28 ||| IN
pulmonary  ||| S:28 E:38 ||| JJ
hypertension  ||| S:38 E:51 ||| NN
trials  ||| S:51 E:58 ||| NNS
With  ||| S:58 E:63 ||| IN
recent  ||| S:63 E:70 ||| JJ
advances  ||| S:70 E:79 ||| NNS
in  ||| S:79 E:82 ||| IN
our  ||| S:82 E:86 ||| PRP$
understanding  ||| S:86 E:100 ||| NN
of  ||| S:100 E:103 ||| IN
pulmonary  ||| S:103 E:113 ||| JJ
hypertension  ||| S:113 E:126 ||| NN
and  ||| S:126 E:130 ||| CC
with  ||| S:130 E:135 ||| IN
ever  ||| S:135 E:140 ||| RB
increasing  ||| S:140 E:151 ||| VBG
therapeutic  ||| S:151 E:163 ||| JJ
options  ||| S:163 E:171 ||| NNS
at  ||| S:171 E:174 ||| IN
our  ||| S:174 E:178 ||| PRP$
disposal ||| S:178 E:186 ||| NN
,  ||| S:186 E:188 ||| ,
it  ||| S:188 E:191 ||| PRP
remains  ||| S:191 E:199 ||| VBZ
disappointing  ||| S:199 E:213 ||| JJ
that  ||| S:213 E:218 ||| IN
clinical  ||| S:218 E:227 ||| JJ
markers  ||| S:227 E:235 ||| NN
of  ||| S:235 E:238 ||| IN
disease  ||| S:238 E:246 ||| NN
progression  ||| S:246 E:258 ||| NNS
remain  ||| S:258 E:265 ||| VBP
dated ||| S:265 E:270 ||| VBN
.  ||| S:270 E:272 ||| .
There  ||| S:272 E:278 ||| EX
has  ||| S:278 E:282 ||| VBZ
long  ||| S:282 E:287 ||| RB
been  ||| S:287 E:292 ||| VBN
a  ||| S:292 E:294 ||| DT
search  ||| S:294 E:301 ||| NN
for  ||| S:301 E:305 ||| IN
a  ||| S:305 E:307 ||| DT
more  ||| S:307 E:312 ||| RBR
robust  ||| S:312 E:319 ||| JJ
clinical  ||| S:319 E:328 ||| JJ
correlate  ||| S:328 E:338 ||| NN
than  ||| S:338 E:343 ||| IN
the  ||| S:343 E:347 ||| DT
6  ||| S:347 E:349 ||| CD
minute  ||| S:349 E:356 ||| NN
walk  ||| S:356 E:361 ||| NN
test ||| S:361 E:365 ||| NN
.  ||| S:365 E:367 ||| .
Resting  ||| S:367 E:375 ||| JJ
right  ||| S:375 E:381 ||| NN
heart  ||| S:381 E:387 ||| NN
pressures  ||| S:387 E:397 ||| NNS
do  ||| S:397 E:400 ||| VBP
not  ||| S:400 E:404 ||| RB
increase  ||| S:404 E:413 ||| VB
linearly  ||| S:413 E:422 ||| VBN
with  ||| S:422 E:427 ||| IN
worsening  ||| S:427 E:437 ||| VBG
disease ||| S:437 E:444 ||| NN
,  ||| S:444 E:446 ||| ,
limiting  ||| S:446 E:455 ||| VBG
their  ||| S:455 E:461 ||| PRP$
use  ||| S:461 E:465 ||| NN
as  ||| S:465 E:468 ||| IN
primary  ||| S:468 E:476 ||| JJ
endpoints ||| S:476 E:485 ||| NN
.  ||| S:485 E:487 ||| .
Some  ||| S:487 E:492 ||| DT
progress  ||| S:492 E:501 ||| NN
has  ||| S:501 E:505 ||| VBZ
been  ||| S:505 E:510 ||| VBN
made  ||| S:510 E:515 ||| VBN
however ||| S:515 E:522 ||| RB
,  ||| S:522 E:524 ||| ,
with  ||| S:524 E:529 ||| IN
' ||| S:529 E:530 ||| POS
time  ||| S:530 E:535 ||| NN
to  ||| S:535 E:538 ||| TO
clinical  ||| S:538 E:547 ||| JJ
worsening ||| S:547 E:556 ||| NN
'  ||| S:556 E:558 ||| ''
a  ||| S:558 E:560 ||| DT
composite  ||| S:560 E:570 ||| JJ
endpoint  ||| S:570 E:579 ||| NN
of  ||| S:579 E:582 ||| IN
several  ||| S:582 E:590 ||| JJ
markers  ||| S:590 E:598 ||| NN
of  ||| S:598 E:601 ||| IN
disease  ||| S:601 E:609 ||| NN
severity ||| S:609 E:617 ||| NN
.  ||| S:617 E:619 ||| .
Trials  ||| S:619 E:626 ||| NNS
have  ||| S:626 E:631 ||| VBP
also  ||| S:631 E:636 ||| RB
been  ||| S:636 E:641 ||| VBN
undertaken  ||| S:641 E:652 ||| VBN
to  ||| S:652 E:655 ||| TO
evaluate  ||| S:655 E:664 ||| VB
the  ||| S:664 E:668 ||| DT
merits  ||| S:668 E:675 ||| NNS
of  ||| S:675 E:678 ||| IN
echocardiographic  ||| S:678 E:696 ||| JJ
indices ||| S:696 E:703 ||| NNS
,  ||| S:703 E:705 ||| ,
cardio  ||| S:705 E:712 ||| JJ
pulmonary  ||| S:712 E:722 ||| JJ
exercise  ||| S:722 E:731 ||| NN
testing  ||| S:731 E:739 ||| NN
and  ||| S:739 E:743 ||| CC
cardiac  ||| S:743 E:751 ||| JJ
MRI ||| S:751 E:754 ||| NNP
,  ||| S:754 E:756 ||| ,
with  ||| S:756 E:761 ||| IN
mixed  ||| S:761 E:767 ||| JJ
results ||| S:767 E:774 ||| NNS
.  ||| S:774 E:776 ||| .
With  ||| S:776 E:781 ||| IN
the  ||| S:781 E:785 ||| DT
lack  ||| S:785 E:790 ||| NN
of  ||| S:790 E:793 ||| IN
a  ||| S:793 E:795 ||| DT
sensitive  ||| S:795 E:805 ||| JJ
and  ||| S:805 E:809 ||| CC
specific  ||| S:809 E:818 ||| JJ
biomarker  ||| S:818 E:828 ||| NN
for  ||| S:828 E:832 ||| IN
pulmonary  ||| S:832 E:842 ||| JJ
hypertension ||| S:842 E:854 ||| NN
,  ||| S:854 E:856 ||| ,
the  ||| S:856 E:860 ||| DT
goal  ||| S:860 E:865 ||| NN
of  ||| S:865 E:868 ||| IN
finding  ||| S:868 E:876 ||| VBG
a  ||| S:876 E:878 ||| DT
reproducible  ||| S:878 E:891 ||| JJ
endpoint  ||| S:891 E:900 ||| NN
that  ||| S:900 E:905 ||| WDT
accurately  ||| S:905 E:916 ||| RB
reflects  ||| S:916 E:925 ||| VBZ
disease  ||| S:925 E:933 ||| NN
severity  ||| S:933 E:942 ||| NN
and  ||| S:942 E:946 ||| CC
prognosis  ||| S:946 E:956 ||| NN
remains  ||| S:956 E:964 ||| VBZ
elusive ||| S:964 E:971 ||| JJ
.  ||| S:971 E:973 ||| .
In  ||| S:973 E:976 ||| IN
this  ||| S:976 E:981 ||| DT
article  ||| S:981 E:989 ||| NN
we  ||| S:989 E:992 ||| PRP
discuss  ||| S:992 E:1000 ||| VB
relevant  ||| S:1000 E:1009 ||| JJ
endpoints  ||| S:1009 E:1019 ||| NN
and  ||| S:1019 E:1023 ||| CC
focus  ||| S:1023 E:1029 ||| NN
on  ||| S:1029 E:1032 ||| IN
exercise  ||| S:1032 E:1041 ||| NN
haemodynamics  ||| S:1041 E:1055 ||| NN
as  ||| S:1055 E:1058 ||| IN
a  ||| S:1058 E:1060 ||| DT
primary  ||| S:1060 E:1068 ||| JJ
endpoint  ||| S:1068 E:1077 ||| NN
for  ||| S:1077 E:1081 ||| IN
clinical  ||| S:1081 E:1090 ||| JJ
trials ||| S:1090 E:1096 ||| NNS
.  ||| S:1096 E:1098 ||| .
